Ⓐ
PeptiBrief
Research peptide

Cagrilintide

Cagrilintide is a research peptide indexed in the PeptiBrief evidence database.

Evidence confidence

Human
2/5
Some human clinical evidence
1 citation
Animal
Not yet assessed
Trust Engine review pending.
Mechanistic
Not yet assessed
Trust Engine review pending — see editorial links below.
Editorial evidence links exist, but this category has not yet completed Trust Engine assessment.
Safety
2/5
Partially characterised safety
1 citation

Claimed uses

Mechanisms

Safety notes

Long-term safety, validated dosing and product quality may be uncertain outside formal clinical development.

Regulation
  • Investigational and not approved as a standalone prescription medicine for weight management in major jurisdictions at the time of this evidence summary.
  • Not approved for general wellness or performance use unless a specific regulated product and indication exists.

References

  1. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial · 2021
Last reviewed
12 July 2026
Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.